Skip to main content
Clinical Trials/CTRI/2023/03/050213
CTRI/2023/03/050213
Not Yet Recruiting
Phase 3

A prospective single centre observational study to evaluate effectiveness and safety of Saroglitazar 4mg Vs Obeticholic acid 10 mg in pateints with non alcoholic fatty liver disease ( NAFLD)/ Non alcoholic Steatohepatitis (NASH). - OCASAR in NAFLD/ NASH

Department of Medical gastroenterology0 sites0 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Health Condition 1: K740- Hepatic fibrosis
Sponsor
Department of Medical gastroenterology
Status
Not Yet Recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional

Investigators

Sponsor
Department of Medical gastroenterology

Eligibility Criteria

Inclusion Criteria

  • Adults (age 18 to 60\) being managed or treated for NAFLD.
  • The patient must qualify for NAFLD, according to the American Association for the Study of Liver Diseases (AASLD) criteria (Chalasani et al.2017\).
  • (a) There is hepatic steatosis by imaging or histology,
  • (b) There is no significant alcohol consumption,
  • (c) There are no competing aetiologies for hepatic steatosis
  • (d) There are no co\-existing causes for chronic liver disease.
  • Patientâ??s demonstration of understanding of study requirements and treatment procedures, willingness to comply with all protocol\-required evaluations.
  • The subjects underwent Fibroscan per the protocol described prior to enrolment and subsequently, they were contacted to participate in the follow\-up study at 24 .
  • The lipid profile range in the inclusion criteria. TG \>\= 150mg/dl and LDL \>\= 100mg /dL and HDL \<\= 40 mg /dL.

Exclusion Criteria

  • Presence of regular or excessive use of alcohol within 2 years prior to initial screening.
  • Presence of alternative causes of fatty liver, including:
  • History of bowel surgery, gastrointestinal (bariatric) surgery or undergoing evaluation for bariatric surgery for obesity, extensive small\-bowel resection, or orthotopic liver transplants (OLT)
  • History of other chronic liver disease (Viral hepatitis B or C, autoimmune hepatitis, cholestatic and metabolic liver diseases) and hemochromatosis

Outcomes

Primary Outcomes

Not specified

Similar Trials